Market revenue in 2023 | USD 74.2 million |
Market revenue in 2030 | USD 651.3 million |
Growth rate | 36.4% (CAGR from 2023 to 2030) |
Largest segment | Inflammatory & autoimmune disorders |
Fastest growing segment | Inflammatory & Autoimmune Disorders |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Inflammatory & Autoimmune Disorders |
Key market players worldwide | Amgen Inc, Roche Holding AG, Genentech, Akeso Inc Ordinary Shares, Janssen Pharmaceuticals, Taisho Pharmaceutical Holdings Co Ltd ADR, Immunocore Holdings PLC ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to bispecific antibodies market will help companies and investors design strategic landscapes.
Inflammatory & autoimmune disorders was the largest segment with a revenue share of 100% in 2023. Horizon Databook has segmented the Japan bispecific antibodies market based on inflammatory & autoimmune disorders covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan bispecific antibodies market , including forecasts for subscribers. This country databook contains high-level insights into Japan bispecific antibodies market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account